Prevention of cervical cancer in Central and Eastern Europe and Central Asia: a challenge for the future (Q44037258)

29 November 2017

title

Prevention of cervical cancer in Central and Eastern Europe and Central Asia: a challenge for the future (English)

1 reference

29 November 2017

0 references

1 reference

cervix uterine cancer

1 reference

Vesna Kesic

1

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 December 2013

1 reference

29 November 2017

1 reference

29 November 2017

volume

31 Suppl 7

1 reference

29 November 2017

page(s)

vii-ix

1 reference

Trends in cervical cancer incidence and mortality in the Baltic countries, Bulgaria and Romania

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.105

Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.105

Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.105

Self-reported sexual debut and behavior in young adults aged 18-24 years in seven European countries: implications for HPV vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.105

Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.105

Human papillomavirus, human immunodeficiency virus and immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.105

Challenges in starting organised screening programmes for cervical cancer in the new member states of the European Union

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.105

Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.105

Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.105

Primary HPV screening for cervical cancer prevention: results from European trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.105

Process of care failures in invasive cervical cancer: systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.105

Trials comparing cytology with human papillomavirus screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.105

HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.105

HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.105

Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.105

Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.105

Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.105

Recommendations for cervical cancer prevention in Central and Eastern Europe and Central Asia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.11.105

10.1016/J.VACCINE.2012.11.105

7 January 2021

Identifiers

DOI

1 reference

29 November 2017

1 reference